In this installment of Med Op-Ed: Why is it so hard to stop eating a sweet-and-salty cookie? Does bariatric surgery still have a role in obesity treatment? Could microdosing tirzepatide make treatment more affordable and accessible — or is it a shortcut with unacceptable risk?

The Sea Salt Cookie Trick That Fuels Overeating

Foods that mix contrasting flavors and textures (like a sweet-and-salty cookie) may keep people eating past the point of fullness. The contrast keeps food tasting good, slows down the natural drop in appetite that comes from eating the same flavor repeatedly, and retriggers the brain's reward response. Reducing flavor variety in a meal — or using medications that affect reward pathways, such as GLP-1s — may help patients stop eating sooner and eat less overall. Writing in Obesity, Mohammed Ayyad, MD, and Eugene Kim, MD, suggested that clinicians counseling patients on eating habits should pay attention to how foods are flavored and textured, since this may be a practical, modifiable target for supporting weight management.

The Context

• Adding variety to a meal makes people eat more. In lab studies, offering different flavors or condiments during a meal increased how much food people ate — by as much as 40% — compared to eating the same plain food throughout. 
• A diet high in processed foods leads to overeating and weight gain. In a controlled hospital study, people eating an ultraprocessed diet consumed about 500 extra calories per day compared to a matched whole-food diet — and gained weight within just 2 weeks. Many processed foods are designed with layered flavors, textures, and aromas that may drive this effect. 
• GLP-1s may curb the urge to keep eating. Brain imaging and clinical trials show that GLP-1 medications lower the brain's response to food rewards and cravings and reduce how much people want or crave high-fat foods — suggesting they help people feel satisfied sooner.

In Their Own Words

"For clinicians, this framework may encourage greater attention to sensory composition and flavor pairing when counseling patients about eating patterns and highlights modifiable features of food design as potential intervention targets to improve hedonic control of food intake and support sustainable weight management."

Read it: How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity

Bariatric Surgery's Role in GLP-1 Era

Metabolic bariatric surgery (MBS) shouldn't be seen as competing with rapidly advancing pharmacotherapy, endoscopic techniques, and digital tools, but as one part of an integrated, stage-adapted care continuum. Clinicians should avoid both over-medicalizing preclinical risk and delaying surgery for those who'd benefit most, basing treatment on disease severity, phenotype, comorbidities, and patient preference within a coordinated, multidisciplinary model, wrote Ricardo V. Cohen, MD, and colleagues in the International Journal of Obesity.

The Context

• Treatment decisions should hinge on the key clinical distinction between preclinical obesity (elevated risk, no organ dysfunction) and clinical obesity (established disease with functional impairment) — not on weight-loss magnitude alone.
• Patients with clinical obesity and significant metabolic, mechanical, or organ-level complications remain strong candidates for MBS, given its durability, safety, and superior long-term cost-effectiveness versus lifelong medication. MBS may be appropriate after medication-induced weight loss when adverse events, cost, or preference limit continued therapy. Decisions should be based on baseline severity, with partial/transient responders escalated rather than reclassified.
• Obesity management medications can serve as an effective entry point into care, though some patients will still need to escalate to surgery.

In Their Own Words:

"Treatment selection should remain grounded in multidisciplinary assessment and shared decision-making, considering phenotype, risk profile, expected durability of response, and patient preference."

Read it: Where does surgery fit in the era of effective obesity pharmacotherapy? Positioning metabolic bariatric surgery within multimodal obesity care

Microdosing Tirzepatide: Promise and Peril

Microdosing tirzepatide is proposed as an off-label, flexible strategy to enhance access, affordability, and tolerability, but it is not well studied and carries safety, dosing, and medicolegal risks that require cautious implementation, stringent aseptic technique, and clear patient instruction; prospective evaluation is needed, wrote Anne M. Komé, PharmD, and colleagues in Diabetes, Obesity, and CardioMetabolic CARE.

The Context

• Potential clinical advantages include flexible titration for tolerance and transitions of care, clearer dosing with syringe markings, direct access via home delivery, lower cash prices for higher-strength single-dose vials when refilled within 45 days, and reduced waste by extending days' supply.
• Tolerability may improve with initiation or maintenance at lower doses; weekly subcutaneous administration is maintained, and U-100 insulin syringes with half-unit demarcations can aid accurate measurements using the smallest appropriate syringe.
• Key risks include contamination and unknown peptide stability when re-entering preservative-free single-dose vials, uncertain stopper integrity, infection risk after beyond-use date, and potential for dosing errors in patients with low visibility or dexterity. Implementation safeguards include recognizing off-label and medicolegal implications, providing clear written and verbal instructions, adhering to manufacturer discard timelines (immediate for single-dose; 30 days for multi-dose), cleaning stoppers with alcohol, refrigerating between uses, avoiding high temperatures, never reusing needles, close follow-up for dose adjustments, and monitoring efficacy with therapy modification as needed.

In Their Own Words

"Microdosing is an off-label strategy involving the use of fractional doses when standard GLP-1 dosing is not ideal or is cost prohibitive…Prescribers should recognize that microdosing is off-label and may have medicolegal implications."

Read it: 

Weighing the Risks and Benefits of Microdosing Tirzepatide Vials

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

to food rewards and cravings and reduce how much people want or crave high-fat foods — suggesting they help people feel satisfied sooner.